Continued Benefit, More Toxicity With First-Line Osimertinib Plus Chemo in NCSLC Liam Davenport March 25, 2024

https://www.medscape.com/viewarticle/continued-benefit-more-toxicity-first-line-osimertinib-plus-2024a10005n1?src=